Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -77.42M | -244.83M | -229.65M | -254.87M | -219.71M |
| Total Depreciation and Amortization | 1.15M | 937.00K | 840.00K | 820.00K | 843.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.39M | 220.48M | 208.34M | 202.74M | 162.74M |
| Change in Net Operating Assets | -5.79M | -16.55M | -42.39M | -7.00M | 4.97M |
| Cash from Operations | -23.67M | -39.96M | -62.86M | -58.31M | -51.16M |
| Capital Expenditure | -9.09M | -8.45M | -2.25M | -678.00K | -206.00K |
| Sale of Property, Plant, and Equipment | 351.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | 6.56M | 6.56M | 6.56M | 6.56M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 0.00 | 28.25M |
| Cash from Investing | -8.74M | -1.89M | 4.31M | 5.88M | 34.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -24.87M | -27.46M | -27.46M |
| Issuance of Common Stock | 128.49M | 127.65M | 3.23M | 3.11M | 231.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 40.00M | 60.25M | 60.25M | 60.25M | 20.25M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -66.00K | -6.17M | -6.17M | -6.17M | -6.17M |
| Cash from Financing | 168.43M | 181.73M | 32.44M | 29.74M | -13.15M |
| Foreign Exchange rate Adjustments | -21.00K | 10.00K | 5.00K | -37.00K | -53.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.99M | 139.89M | -26.11M | -22.73M | -29.75M |